Prime Medicine, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Prime Medicine, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-21.9×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 59% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
2/3 · 1/3Sales grew in 2 of the last 3 years; profit grew in 1 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-20.0×Operating cash was negative last year, while some debt falls due within a year.
Lower than 55% of Healthcare companies in United States.
Cash Cushion Ratio
+9%Cash, after subtracting all debt, equals 9% of its market value (net cash).
Higher than 50% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Prime Medicine, Inc. made a loss over the last year. Prime Medicine, Inc. owes $0.84 for every $1 it owns. Prime Medicine, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossPrime Medicine, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.34The share price is 0.34 times Prime Medicine, Inc.'s book value per share, lower than 95% of Healthcare companies in United States.
Market cap
$677 MThe total market value of all of Prime Medicine, Inc.'s shares at today's price (share price × number of shares), larger than 59% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$2.0 BWhat Prime Medicine, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$11.02Net worth divided by the number of shares. The share price of $3.73 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-373.3%Prime Medicine, Inc. lost 373.3% of its shareholders' money over the last year, lower than 91% of Healthcare companies in United States.
Owes vs Owns
0.84×Prime Medicine, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Dividend yield
NonePrime Medicine, Inc. does not currently pay a dividend.
Revenue growth
+55%Revenue rose 55% in the year to Dec 2025.
Profit growth
LossPrime Medicine, Inc. made a loss in each of the last two years.
Profit margin
-4342.4%Prime Medicine, Inc. lost $4342 for every $100 of revenue.
Cash vs debt
Net cashPrime Medicine, Inc. held $61 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Prime Medicine, Inc.: $677 M ÷ $2.0 B (30 Jun 2026) = 0.3.
What is Prime Medicine, Inc.'s return on equity?
Prime Medicine, Inc. lost 373.3% of its shareholders' money over the last year, lower than 91% of Healthcare companies in United States.
How much does Prime Medicine, Inc. owe compared with what it owns?
Prime Medicine, Inc. owes $0.84 for every $1 it owns (high), higher than 80% of Healthcare companies in United States.
Does Prime Medicine, Inc. pay a dividend?
No. Prime Medicine, Inc. does not currently pay a dividend.
Is Prime Medicine, Inc.'s revenue growing?
Revenue rose 55% in the year to Dec 2025.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.